Companies › I-Mab Biopharma US
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TJ033721 (givastomig) anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 2 | Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04900818 | TJ033721 (givastomig) | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
| NCT07432295 | TJ033721 (givastomig) | Phase 2 | Solid Tumor | Oncology | Mar 2030 |
NingBo Junyan Hongshi Biosciences Biokin (Shanghai) Biopharmaceutical CrystalGenomics Partner Therapeutics STCube
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.